Refine by
Cryopreservation Articles & Analysis: Older
26 news found
Equally, cryopreservation is a relatively violent process in which freezing and thawing methods can cause physical and chemical stress on cells, resulting in changes in the cell surface markers and function. Among PBMCs, monocytes are particularly sensitive to these freeze-thaw insults, and have been reported to show unfavourable alterations in yield, function, and gene ...
Mammalian cell lines including Vero cells are generally amenable to cryopreservation, and this makes it possible to prepare reliable Cell Banks of homogenous aliquots that can be stored in a stable state at ultra-low temperature. ...
ByNuvonis
Poster 159: Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers” Highlights: CYNK-101 is a cryopreserved off the shelf allogeneic NK cell product, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 ...
Senti Bio's oncology pipeline uses healthy adult donor-derived, natural killer (NK) cells engineered with chimeric antigen receptor (CAR) gene circuits that are cryopreserved and dosed off-the-shelf. Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target ...
(Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), ...
(Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), ...
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 ...
Senti Bio's oncology pipeline uses healthy adult donor-derived, natural killer (NK) cells engineered with chimeric antigen receptor (CAR) gene circuits that are cryopreserved and dosed off-the-shelf. “We have made tremendous progress over the last year in advancing multiple oncology programs toward the clinic. ...
(Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), ...
” First Quarter Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from human placental CD34+ cells. ...
The poster also demonstrated the feasibility of cryopreserving AFM28 pre-complexed with NK cells whilst maintaining anti-tumor activity suggesting the promise for an off-the-shelf therapy targeting leukemic blasts and leukemic stem cells in patients with AML and MDS. ...
” Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from human placental CD34+ cells. ...
At its new CGB facility, CHA Medical & Bio Group will integrate its proprietary cell separation, cell culture, and cryopreservation technologies with its wide range of services to provide more optimized and customized approaches to cell and gene therapy development. ...
In the STEADFAST clinical study, each patient undergoes a leukapheresis procedure to collect their white blood cells, after which their Treg cells are isolated, genetically engineered and then cryopreserved. The patient subsequently undergoes transplantation surgery to receive a kidney from a living donor. ...
They are subjected to extensive testing throughout production and prior to use, including identity, purity, potency, and safety analyses. The final product is cryopreserved and maintained as individual “off-the-shelf” doses for administration via percutaneous injection in an outpatient setting. ...
(Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), ...
—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. ...
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. ...
Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML). ...
Cellular Immunotherapies: Basic and Translational: Poster II Presentation date/time: Sunday, 12 December 2021; 6:00 pm Room: Georgia World Congress Center, Hall B5 Highlights: CYNK-101 is a cryopreserved, off the shelf, allogeneic NK cell product candidate, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant. ...